Search research articles
Contact Us
Filters
Showing results (821-830 of 848) with videos related to
Page
of 85
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients
A R Mato, B T Hill, N Lamanna, et al.
Journal of the American Chemical Society
|
May 8, 2019
Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening
Efrat Resnick, Anthony Bradley, Jinrui Gan, et al.
Nature Medicine
|
July 21, 2015
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H Wilson, Ryan M Young, Roland Schmitz, et al.
Biorxiv : the Preprint Server for Biology
|
September 4, 2024
Discovery of potent SARS-CoV-2 nsp3 macrodomain inhibitors uncovers lack of translation to cellular antiviral response
Alpha A Lee, Isabelle Amick, Jasmin C Aschenbrenner, et al.
Blood
|
July 27, 2016
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
Anita Kumar, Carla Casulo, Joachim Yahalom, et al.
Blood
|
December 1, 2020
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy
Anthony R Mato, Nilanjan Ghosh, Stephen J Schuster, et al.
Annals of the New York Academy of Sciences
|
March 24, 2023
Exosomes, microvesicles, and other extracellular vesicles-a Keystone Symposia report
Jennifer Cable, Kenneth W Witwer, Robert J Coffey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 28, 2021
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma
Anita Kumar, Carla Casulo, Ranjana H Advani, et al.
Blood
|
January 12, 2024
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL
Jennifer A Woyach, Gabriela Perez Burbano, Amy S Ruppert, et al.
The New England Journal of Medicine
|
December 4, 2018
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
Jennifer A Woyach, Amy S Ruppert, Nyla A Heerema, et al.
Page
of 85
Search research articles
Search
Showing results (821-830 of 848) with videos related to
Sort By:
Page
of 85
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients
A R Mato, B T Hill, N Lamanna, et al.
Journal of the American Chemical Society
|
May 8, 2019
Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening
Efrat Resnick, Anthony Bradley, Jinrui Gan, et al.
Nature Medicine
|
July 21, 2015
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H Wilson, Ryan M Young, Roland Schmitz, et al.
Biorxiv : the Preprint Server for Biology
|
September 4, 2024
Discovery of potent SARS-CoV-2 nsp3 macrodomain inhibitors uncovers lack of translation to cellular antiviral response
Alpha A Lee, Isabelle Amick, Jasmin C Aschenbrenner, et al.
Blood
|
July 27, 2016
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
Anita Kumar, Carla Casulo, Joachim Yahalom, et al.
Blood
|
December 1, 2020
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy
Anthony R Mato, Nilanjan Ghosh, Stephen J Schuster, et al.
Annals of the New York Academy of Sciences
|
March 24, 2023
Exosomes, microvesicles, and other extracellular vesicles-a Keystone Symposia report
Jennifer Cable, Kenneth W Witwer, Robert J Coffey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 28, 2021
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma
Anita Kumar, Carla Casulo, Ranjana H Advani, et al.
Blood
|
January 12, 2024
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL
Jennifer A Woyach, Gabriela Perez Burbano, Amy S Ruppert, et al.
The New England Journal of Medicine
|
December 4, 2018
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
Jennifer A Woyach, Amy S Ruppert, Nyla A Heerema, et al.
Page
of 85